S. Faderl

发表

The biology of chronic myeloid leukemia.

Z. Estrov, R. Kurzrock, H. Kantarjian, 1999, The New England journal of medicine.

Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML

Z. Estrov, G. Garcia-Manero, J. Cortes, 2013, Leukemia.

Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, S. Verstovsek, 2003, Leukemia research.

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

E. Estey, F. Appelbaum, H. Kantarjian, 2014, Leukemia.

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

E. Anaissie, H. Kantarjian, G. Garcia-Manero, 2004, Clinical Cancer Research.

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Leukemia.

Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules

J. Issa, H. Kantarjian, G. Garcia-Manero, 2005 .

Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation

Z. Estrov, H. Kantarjian, G. Garcia-Manero, 2013, Leukemia.

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

Z. Estrov, H. Kantarjian, J. Cortes, 2002, Cancer Chemotherapy and Pharmacology.

A phase I study of the combination of a DNA topoisomerase inhibitor, idarubicin, with the histone deacetylase inhibitor vorinostat, in advanced acute leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2007 .

Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clofarabine with high dose cytarabine and granulocyte colony‐stimulating factor (G‐CSF) priming for relapsed and refractory acute myeloid leukaemia

E. Estey, B. Storer, D. Stirewalt, 2011, British journal of haematology.

Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL).

C. Wilson, H. Kantarjian, G. Garcia-Manero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.

H. Kantarjian, J. Cortes, E. Jabbour, 2010 .

Phase II Study of SU 5416 , a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor , in Patients with Refractory Multiple Myeloma

E. Anaissie, H. Kantarjian, G. Garcia-Manero, 2004 .

Phase I/II study of idarubicin (Ida), high-dose ara-C, and sorafenib (S) in patients (pts) younger than 65 years with acute myeloid leukemia (AML).

M. Andreeff, H. Kantarjian, G. Garcia-Manero, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission

J. Issa, Z. Estrov, H. Kantarjian, 2012, Leukemia.

Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, S. Pierce, 2016, Leukemia.

Lenalidomide: an emerging option in chronic lymphocytic leukemia

J. Reuben, M. Keating, S. O'brien, 2009 .

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia

M. Minden, G. Curt, H. Kantarjian, 2012, Investigational New Drugs.

The prognostic significance of p16INK4a/p14ARF and p15INK4b deletions in adult acute lymphoblastic leukemia.

Z. Estrov, H. Kantarjian, J. Cortes, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia.

H. Kantarjian, J. Cortes, F. Cabanillas, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic score for patients with lower risk myelodysplastic syndrome

H. Kantarjian, G. Garcia-Manero, Xuelin Huang, 2008, Leukemia.

Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications

J. Cortes, M. Keating, A. Glassman, 1999, Leukemia.

Bone marrow cyclooxygenase‐2 levels are elevated in chronic‐phase chronic myeloid leukaemia and are associated with reduced survival

H. Kantarjian, T. Manshouri, M. Talpaz, 2002, British journal of haematology.

Phase 1 and Extension Study of Clofarabine plus Cyclophosphamide in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia ( ALL )

J. Cortes, T. Kadia, F. Ravandi, 2014 .

Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL)

S. Verstovsek, S. O'brien, J. Jorgensen, 2005 .

Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution

H. Kantarjian, F. Ravandi, G. Borthakur, 2009, Leukemia.

Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.

E. Estey, H. Kantarjian, G. Garcia-Manero, 2005, Leukemia research.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2013, Clinical lymphoma, myeloma & leukemia.

Combined fludarabine, cyclophosphamide, and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia

M. Andreeff, H. Kantarjian, J. Cortes, 2001 .

Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia.

G. Garcia-Manero, J. Cortes, T. Kadia, 2011, Journal of Clinical Oncology.

Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL).

M. Andreeff, H. Kantarjian, J. Cortes, 2010 .

Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia

E. Estey, B. Storer, F. Appelbaum, 2013, Haematologica.

Phase II study of vorinostat (V) in combination with idarubicin and high-dose cytarabine (IA) as front-line therapy in patients (pts) with high-risk myelodyplsatic syndrome (MDS) or acute myeloid leukemia (AML).

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2009, Journal of Clinical Oncology.

Phase II study of combination of the hyperCVAD regimen with dasatinib in patients (pts) with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)

H. Kantarjian, J. Cortes, F. Ravandi, 2008 .

New treatment approaches for chronic myelogenous leukemia.

H. Kantarjian, M. Talpaz, S. O'brien, 2000, Seminars in Oncology.

The combination of rituximab and GM-CSF in elderly patients with chronic lymphocytic leukemia (CLL).

J. Reuben, M. Keating, S. O'brien, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage Therapy with Combined Cyclophosphamide (C), Fludarabine (F), Alemtuzumab (A), and Rituximab (R) (CFAR) for Heavily Pre-Treated Patients with CLL.

M. Andreeff, G. Garcia-Manero, J. Cortes, 2005 .

Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR), an Active Frontline Regimen for High-Risk Patients with CLL.

Z. Estrov, G. Garcia-Manero, S. Verstovsek, 2007 .

Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).

H. Kantarjian, S. O'brien, J. Burger, 2010 .

Comparison of fludarabine (F) plus cyclophosphamide (C) versus FC plus rituximab (R) in previously untreated Rai stage III/IV chronic lymphocytic leukemia (CLL).

H. Kantarjian, M. Keating, S. O'brien, 2010 .

Prevalence of venous thromboembolism (VTE) among patients (pts) with acute leukemia (AL) prior to treatment.

H. Kantarjian, S. Faderl, N. Luong, 2011, Journal of Clinical Oncology.

Phase I trial of intermittent administration of sorafenib (BAY 43–9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

M. Konopleva, H. Kantarjian, J. Cortes, 2007 .

A phase II study of fludarabine (F), cyclophosphamide (C), and mitoxantrone (M) plus rituximab (R) (FCM-R) in previously untreated patients (pts) with CLL ≤ 70 years (yrs).

H. Kantarjian, F. Ravandi, M. Keating, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.